We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial.
- Authors
le Roux, Carel W.; Steen, Oren; Lucas, Kathryn J.; Ekinci, Elif I.; Startseva, Elena; Unseld, Anna; Hussain, Samina Ajaz; Hennige, Anita M.
- Abstract
The article discusses a post hoc analysis of a phase 2 clinical trial on survodutide, a dual agonist for glucagon and GLP-1 receptors, in adults with obesity. The study showed significant weight loss and reductions in blood pressure with survodutide treatment compared to placebo. The results suggest that survodutide may help alleviate cardiovascular risk, regardless of hypertension status at baseline. The study was supported by Boehringer Ingelheim, and the authors disclosed potential conflicts of interest related to the research.
- Subjects
WEIGHT loss; GLUCAGON-like peptide-1 receptor; ANGIOTENSIN-receptor blockers; GLUCAGON receptors; DIASTOLIC blood pressure; EXENATIDE
- Publication
Diabetes, Obesity & Metabolism, 2025, Vol 27, Issue 2, p993
- ISSN
1462-8902
- Publication type
Academic Journal
- DOI
10.1111/dom.16052